Barcelona, 22 of January,2020. ANGIOLITE trial aims to compare the performance between the angiolite SES and an everolimus-eluting stent (EES) in patients with coronary artery disease. This trial is a prospective, randomised, multicentre trial, that compares the restenosis parameters of both stents in de novo coronary lesions.
ANGIOLITE trial 24-month outcomes:
In-stent Late Lumen Loss (LLL): angiolite, 0.04mm vs. EES, 0.08mm
Definite of probable stent thrombosis: angiolite, 1.0% vs. EES, 1.9%
Target Lesion Failure (TLF)*: angiolite, 7.1% vs. EES, 7.6%
* composite of cardiac death, target vessel-related MI or clinically-driven TLR
Neo-intimal thickness: angiolite, 72.1μm vs. EES, 86.4 μm
The trial concludes with promising results demonstrating the non-inferiority in late lumen loss of angiolite vs. the gold standard EES. Efficacy and equivalence are confirmed with the great outcomes of the OCT group.
To read the full article visit https://bit.ly/2RfBwEN
angiolite is a sirolimus-eluting coronary stent specially designed for symptomatic ischemic heart disease due to “de novo” stenotic and re-stenotic lesions located in arteries, as well as for occlusive disease due to acute myocardial infarction located in arteries.